BiologicalDrug
MK-4721 clinical trials
Also written AGS-1C4D4.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses MK-4721 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002CompletedPhase 2Agensys, Inc.NCT01608711Written as AGS-1C4D4
- A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic CancerCompletedPhase 2Astellas Pharma IncNCT00902291Written as AGS-1C4D4
- AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate CancerCompletedPhase 1Astellas Pharma IncNCT00519233Written as AGS-1C4D4
Codes
What other systems call MK-4721 · ClinicalTrials.gg INT006337
- MeSH (NLM) C583063MK-4721One source NLM
- UNII (FDA) L0505LPC7OMK-4721Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583063 | MK-4721 | One source NLM |
| UNII (FDA) | L0505LPC7O | MK-4721 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.